HeartBeam to Discuss Q1 2026 Results and Strategic Progress in Upcoming Earnings Call

HeartBeam (NASDAQ: BEAT) announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026, and to provide strategic updates on key growth initiatives. The company, which focuses on cardiac care innovation, will highlight progress in its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs.

The earnings call comes as HeartBeam advances its platform technology, which aims to transform cardiac monitoring through a cable-free device that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. The company received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. These clearances enable physicians to identify cardiac health trends and acute conditions outside medical facilities, potentially redefining cardiac health management.

Investors and stakeholders can access the full press release at https://ibn.fm/yN939. The company holds over 20 issued patents related to its technology, underscoring its commitment to innovation in cardiac care. HeartBeam's recent regulatory milestones position it to capture market share in the growing remote cardiac monitoring space.

The strategic updates are expected to shed light on the company's commercial traction and product development timeline. With its limited commercial launch underway, HeartBeam is targeting both healthcare providers and patients seeking convenient cardiac monitoring solutions. The extended-wear patch development aims to address continuous monitoring needs, while AI programs are designed to enhance diagnostic accuracy.

HeartBeam's ability to deliver actionable heart intelligence through portable devices could significantly impact patient outcomes by enabling earlier detection of arrhythmias and heart attacks. The company's technology is particularly relevant given the increasing prevalence of cardiovascular diseases and the shift toward decentralized care models.

For ongoing updates, the company's newsroom is available at https://ibn.fm/BEAT. Forward-looking statements in the announcement involve risks and uncertainties, as detailed in the company's SEC filings, including its most recent Annual Report on Form 10-K and subsequent quarterly reports.